Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

Fig. 3

The Kaplan-Meier analysis showed significantly worse OS for no ALP-Bouncing (a) and no PSA-decline of ≥50 % (b). No ALP-Bouncing and no PSA-decline of ≥50 % were the strongest predictors of poor overall survival on Abiraterone therapy

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us